IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients DOI Creative Commons
Maryam Karamikheirabad, Junyue Zhang,

Ae-Ri Ahn

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(11), P. 1526 - 1526

Published: Nov. 13, 2024

Background/Objectives: Interleukin 13 receptor alpha 2 (IL-13Rα2) is a with high affinity for IL-13 and involved in the progression of human cancers. However, studies on role IL-13Rα2 osteosarcoma are limited. Therefore, this study aimed to investigate expression roles osteosarcoma. Methods: This evaluated osteosarcomas by evaluating tumor tissues from 37 cells. Results: Immunohistochemical positivity was an independent indicator shorter overall survival relapse-free patients 26 subpopulations who received adjuvant chemotherapy multivariate analysis. In U2OS KHOS/NP cells, overexpression significantly increased proliferation, migration, invasion all which decreased knockdown IL-13Rα2. Overexpression TGF-β, snail, cyclin D1, BCL2 but BAX, caused decrease these molecules. addition, both vitro vivo, proliferation cells increased, apoptosis under treatment doxorubicin. Knockdown sensitized cytotoxic effect Conclusions: The results suggest that IL13Rα2 might be used as potential prognostic patients. Furthermore, it observed influences resistance chemotherapeutic agent therapeutic trial targeting new strategy osteosarcoma, especially those highly expressing IL13Rα2.

Language: Английский

Advances on immunotherapy for osteosarcoma DOI Creative Commons
Shengnan Yu, Xudong Yao

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 9, 2024

Language: Английский

Citations

37
Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma DOI Creative Commons
Lin Zhang,

Haoming Jiang,

Hongzhi Ma

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 22, 2025

Pediatric osteosarcoma, the most prevalent primary malignant bone tumor in children, is marked by aggressive progression and a generally poor prognosis. Despite advances treatment, including multi-agent chemotherapy, survival rates remain suboptimal, with metastasis, particularly to lungs, contributing significantly mortality. The microenvironment plays crucial role osteosarcoma progression, immune cells such as tumor-associated macrophages T lymphocytes influencing behavior. immunosuppressive environment, dominated M2 macrophages, contributes evasion therapeutic outcomes, though recent findings suggest potential for reprogramming these enhance responses. This review provides comprehensive overview of landscape pediatric focus on their interactions within (TME). It examines impact checkpoints, genetic mutations, inflammatory pathways highlighting contribution disease advancement. Additionally, emerging immunotherapeutic strategies, checkpoint inhibitors, macrophage reprogramming, antibody-based therapies, are summarized detail, showcasing improve outcomes.

Language: Английский

Citations

1
A 10-year bibliometric analysis in the field of osteosarcoma treatment from 2014 to 2023 DOI Creative Commons

Yiguo Shen,

Xiao-Bo Shao,

Jiansong Chen

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 28, 2025

Abstract Objective This paper aims to explore the research hot spot and development trend in osteosarcoma treatment using a bibliometric method based upon Web of Science Core Collection (WoSCC) platform over last decade. Methods The literature related cure which were published from January 2014 December 2023 retrieved database WoSCC made an overall analysis for papers including number articles, distribution countries institutions, author information, keywords, with CiteSpace 6.2.R5. Results A total 3131 retrieved, 2601 articles 530 reviews, has been increasing year by There 415 10,719 institutions participating into study. China’s output was highest relying on its 1490 published, followed United States (548 papers). Shanghai Jiaotong university had largest (121 papers) Central South University ranked second (82 16,816 authors participated Massimo Serra Rizzoli Orthopaedics Institute (27 papers), Dominique Heymann Sheffield (20 visualization keywords software showed that drug resistance, delivery, tumor tissue engineering gene expression have become hotspots field treatment. Drug resistance significantly limits effectiveness current cancer treatments. delivery technology not only enhances targeting efficacy drugs but also helps overcome resistance. stem cells, targeted therapy, microenvironment represent new trends. In particular, plays key role development, progression, it offers numerous potential therapeutic targets. Conclusion Our investigation identified foci treatment, mechanisms, innovations technology, cell analysis, novel therapies, clinical translation engineering.

Language: Английский

Citations

1
NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance DOI Creative Commons
Shaoyan Shi, Xuehai Ou, Chao Liu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 30, 2025

Osteosarcoma, a highly aggressive malignancy with generally poor prognosis, is characterized by tumor cells’ ability to evade immune responses and resist treatment. The nuclear transcription factor NF-κB signaling pathway crucial in regulating inflammatory reactions. It occupies central position the development of osteosarcoma microenvironment. This research aimed explore how influences recruitment polarization tumor-associated macrophages myeloid-derived suppressor cells, both which contribute immunosuppression. Furthermore, facilitates surveillance evasion cells altering expression checkpoint molecules, such as PD-L1. also enhances cell resistance chemotherapy radiotherapy activating anti-apoptotic pathways exacerbating treatment-induced inflammation. Potential therapeutic approaches include using inhibitors, possibly combination overcome mechanisms reshape antitumor responses. A thorough examination NF-κB’s role expected yield novel clinical treatment strategies, significantly improve patient prognosis targeting this key pathway.

Language: Английский

Citations

0
Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies DOI Creative Commons
Mahmoud Zhra, Shahid Akhtar Akhund,

Khalid S. Mohammad

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 520 - 520

Published: April 3, 2025

Osteosarcoma is recognized as the most prevalent primary bone malignancy, primarily affecting children and adolescents. It characterized by its aggressive behavior high metastatic potential, which often leads to poor patient outcomes. Despite advancements in surgical techniques chemotherapy regimens, prognosis for patients with osteosarcoma remains unsatisfactory, survival rates plateauing over past few decades. A significant barrier effective treatment development of resistance, complicates management disease contributes recurrence. This review article aims provide a comprehensive overview recent therapy, particularly overcoming resistance. We begin discussing current standard modalities, including resection conventional agents such methotrexate, doxorubicin, cisplatin. While these approaches have been foundational managing osteosarcoma, they are limited adverse effects variability efficacy among patients. To address challenges, we explore novel pharmacological strategies that aim enhance includes targeted therapies focusing on specific molecular alterations cells immunotherapeutic designed harness body’s immune system against tumors. Additionally, innovative drug delivery systems improve bioavailability existing treatments while minimizing toxicity. The also assesses mechanisms underlying efflux mechanisms, altered metabolism, enhanced DNA repair pathways. By synthesizing research findings, highlight potential new therapeutic resistance mechanisms. Ultimately, this seeks inform future directions clinical practices, underscoring need continued innovation treating outcomes rates.

Language: Английский

Citations

0
IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients DOI Creative Commons
Maryam Karamikheirabad, Junyue Zhang,

Ae-Ri Ahn

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(11), P. 1526 - 1526

Published: Nov. 13, 2024

Background/Objectives: Interleukin 13 receptor alpha 2 (IL-13Rα2) is a with high affinity for IL-13 and involved in the progression of human cancers. However, studies on role IL-13Rα2 osteosarcoma are limited. Therefore, this study aimed to investigate expression roles osteosarcoma. Methods: This evaluated osteosarcomas by evaluating tumor tissues from 37 cells. Results: Immunohistochemical positivity was an independent indicator shorter overall survival relapse-free patients 26 subpopulations who received adjuvant chemotherapy multivariate analysis. In U2OS KHOS/NP cells, overexpression significantly increased proliferation, migration, invasion all which decreased knockdown IL-13Rα2. Overexpression TGF-β, snail, cyclin D1, BCL2 but BAX, caused decrease these molecules. addition, both vitro vivo, proliferation cells increased, apoptosis under treatment doxorubicin. Knockdown sensitized cytotoxic effect Conclusions: The results suggest that IL13Rα2 might be used as potential prognostic patients. Furthermore, it observed influences resistance chemotherapeutic agent therapeutic trial targeting new strategy osteosarcoma, especially those highly expressing IL13Rα2.

Language: Английский

Citations

0